TW200716094A - Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor - Google Patents

Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor

Info

Publication number
TW200716094A
TW200716094A TW095114529A TW95114529A TW200716094A TW 200716094 A TW200716094 A TW 200716094A TW 095114529 A TW095114529 A TW 095114529A TW 95114529 A TW95114529 A TW 95114529A TW 200716094 A TW200716094 A TW 200716094A
Authority
TW
Taiwan
Prior art keywords
methods
pharmaceutical compositions
aromatase inhibitor
combination
phenyl
Prior art date
Application number
TW095114529A
Other languages
Chinese (zh)
Inventor
Madelyn Curto
Melanie Sisson
Andrew George Lee
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200716094A publication Critical patent/TW200716094A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-(-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5, 6, 7, 8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt or prodrug thereof and an aromatase inhibitor. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt or prodrug and an aromatase inhibitor selected from aminoglutethimide; formestane; atamestane; anastrazole; fadrozole; finrozole; letrozole; vorozole; 4-[N-(4-bromobenzyl)-N-(4-cyanophenyl)amino]-4H-1,2,4-triazole or exemestane, or a pharmaceutically acceptable salt thereof.
TW095114529A 2005-04-25 2006-04-24 Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor TW200716094A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67480705P 2005-04-25 2005-04-25

Publications (1)

Publication Number Publication Date
TW200716094A true TW200716094A (en) 2007-05-01

Family

ID=36693972

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095114529A TW200716094A (en) 2005-04-25 2006-04-24 Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor

Country Status (6)

Country Link
EP (1) EP1937251A2 (en)
JP (1) JP2006306872A (en)
AR (1) AR054258A1 (en)
CA (1) CA2605796A1 (en)
TW (1) TW200716094A (en)
WO (1) WO2006114702A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9693953B2 (en) 2006-06-02 2017-07-04 Janet A. Chollet Method of treating atrophic vaginitis
EP2070943A1 (en) * 2007-12-14 2009-06-17 Crystal Pharma, S.A. Process for obtaining 6-Alkylidenandrost-1,4-diene-3one
EP2450354B1 (en) * 2009-07-03 2016-08-17 Riken Labeling compound for pet
JP6280501B2 (en) 2011-09-08 2018-02-14 メレオ バイオファーマ ２ リミテッド Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
BR112018072286A2 (en) 2016-04-29 2019-02-12 Yale University targeted measure of hormone receptor-related transcriptional activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
MXPA03001983A (en) * 2000-09-08 2003-06-24 Pharmacia Italia Spa Exemestane as chemopreventing agent.
AR034142A1 (en) * 2000-09-08 2004-02-04 Sloan Kettering Inst Cancer A PHARMACEUTICAL COMPOSITION, METHOD FOR MANUFACTURING A MEDICINAL BASED ON SUCH COMPOSITION AND USE OF THE COMPOSITION
WO2003017973A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
EP1435967A2 (en) * 2001-10-10 2004-07-14 Pharmacia Italia S.p.A. Methods for preventing and treating bone loss with steroid compounds
UA84046C2 (en) * 2004-01-13 2008-09-10 Уайет Treatment of aromatase inhibitor therapy-related osteoporosis
CN101052655A (en) * 2004-11-04 2007-10-10 辉瑞产品有限公司 CTLA-4 antibody and aromatase inhibitor combination of treatment for breast cancer

Also Published As

Publication number Publication date
JP2006306872A (en) 2006-11-09
EP1937251A2 (en) 2008-07-02
CA2605796A1 (en) 2006-11-02
WO2006114702A3 (en) 2007-01-04
WO2006114702A2 (en) 2006-11-02
AR054258A1 (en) 2007-06-13

Similar Documents

Publication Publication Date Title
ATE504565T1 (en) AZETIDINES AS MEK INHIBITORS IN THE TREATMENT OF PROLIFERATIVE DISEASES
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
CY1109860T1 (en) FACTORS OF HISTAMIN H3 CONTAINERS, PREPARATION AND THERAPEUTIC USES
JP2010521483A5 (en)
TW200624427A (en) Heterocyclic derivatives and their use as therapeutic agents
NZ593593A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
NZ626985A (en) Combination therapy (vemurafenib and a mdm2 inhibitor) for the treatment proliferative disorders
TW200626139A (en) Heterocyclic derivatives and their use as therapeutic agents
ATE371656T1 (en) HETEROARYL-PYRIMIDINE DERIVATIVES AS JAK INHIBITORS
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626155A (en) Heterocyclic derivatives and their use as therapeutic agents
EE200300403A (en) N-substituted Non-Aromatic Heterocyclic Compound, Pharmaceutical Composition Containing It, and Use of the Compound as a Pharmaceutical
NO20056192L (en) Capase inhibitors and their use
UA86957C2 (en) Azepinoindole derivatives as pharmaceutical agents
NO20054905L (en) 2-acylamino-4-phenylthiazole derivatives, methods for their preparation and use of the same as in therapeutics
RU2009118254A (en) PHENYLACETAMIDES AS PROTEINKINASE INHIBITORS
UA84146C2 (en) Amides of pyrrolopyridine-2-carboxylic acid as inhibitors of glycogen phosphorylase, method for their synthesis, drug formulation, and their use as therapeutic agents
TW200716094A (en) Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CA2409741A1 (en) Tnf-.alpha. production inhibitors
CA2484188A1 (en) Tachykinin receptor antagonists
ATE522526T1 (en) 4-(3-(2-(PHENYL)MORPHOLINO)-2-OXOPYRROLIDINE-1-Y )-N-(THIAZOL-2-YL)BENZENESULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ION CHANNEL MODULATORS FOR THE TREATMENT OF PAIN
DE602006020871D1 (en) LINEAR UREA MIMETIC ANTAGONISTS OF THE P2Y1 RECEPTOR FOR THE TREATMENT OF THROMBOSELEIDES
WO2005030187A3 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension